Brief: Agios Presents Positive Results From Phase 3 Energize Study Of Mitapivat

Agios Pharmaceuticals

15/06/2024 14:17

June 15 (Reuters) - Agios Pharmaceuticals Inc  AGIO.O :
    * AGIOS PRESENTS POSITIVE RESULTS FROM PHASE 3 ENERGIZE
STUDY OF
MITAPIVAT IN NON-TRANSFUSION-DEPENDENT THALASSEMIA IN PLENARY
SESSION AT THE EUROPEAN HEMATOLOGY ASSOCIATION 2024 HYBRID
CONGRESS
    * ENERGIZE STUDY ACHIEVED ITS PRIMARY ENDPOINT
    * STATISTICAL SIGNIFICANCE WAS ALSO ACHIEVED FOR BOTH KEY
SECONDARY ENDPOINTS

Source text for Eikon:  ID:nGNX9FDp2j 
Further company coverage:  AGIO.O 

 ((Reuters.Briefs@thomsonreuters.com;))